<cite id="uufuy"><noscript id="uufuy"></noscript></cite>
    <rp id="uufuy"></rp>

    A POWERFUL RESEARCH AND
    DEVELOPMENT ENGINE

    Our robust pipeline of investigational product candidates strives to address many serious medical conditions including asthma, pain, cancer and infectious diseases.

    • Phase 1 trials

      Phase 1 Trials

      CEMIPLIMAB*

      PD-1 Antibody
      Cancer

      REGN1979

      CD20 X CD3 Antibody
      Cancer

      CEMIPLIMAB + REGN1979

      PD-1 Antibody + CD20 X CD3 Antibody
      Cancer

      REGN3767

      LAG-3 Antibody
      Cancer

      CEMIPLIMAB + REGN3767

      PD-1 Antibody + LAG-3 Antibody
      Cancer

      REGN5458*

      BCMA X CD3 Antibody
      Cancer

      REGN4018*

      MUC16 X CD3 Antibody
      Cancer

      CEMIPLIMAB + REGN4018*

      PD-1 Antibody + MUC16 X CD3 Antibody
      Cancer

      REGN4659

      CTLA4 Antibody
      Cancer

      REGN3048-3051

      Middle Eastern Respiratory Coronavirus Antibody
      MERS-CoV infection

      POZELIMAB

      C5 Antibody
      Paroxysmal nocturnal hemoglobinuria

      REGN4461

      LEPR Antibody
      Lipodystrophy and obesity

      REGN5069

      GFRα3 Antibody
      Pain
    • Phase 2 trials

      Phase 2 Trials

      CEMIPLIMAB*

      PD-1 Antibody
      Basal cell carcinoma

      DUPILUMAB*

      IL-4R Antibody
      Grass allergy, peanut allergy

      SARILUMAB*

      IL-6R Antibody
      Polyarticular-course juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis

      EVINACUMAB

      ANGPTL-3 Antibody
      Refractory hypercholesterolemia (both HeFH and non-FH), severe hypertriglyceridemia

      REGN1908-1909

      Fel d 1 Antibody
      Cat allergy

      GARETOSMAB

      Activin A Antibody
      Fibrodysplasia Ossificans Progressiva (FOP)

      REGN3500*

      IL-33 Antibody
      Atopic dermatitis, asthma, chronic obstructive pulmonary disease (COPD)
    • Phase 3 trials

      Phase 3 Trials

      ALIROCUMAB*

      PCSK9 Antibody
      Homozygous familial hypercholesterolemia (HoFH) in adults and pediatrics, heterozygous familial hypercholesterolemia in pediatrics

      CEMIPLIMAB*

      PD-1 Antibody
      Non-small cell lung cancer, cervical cancer

      DUPILUMAB*

      IL-4R Antibody
      Atopic dermatitis in pediatrics, asthma in pediatrics, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis, chronic obstructive pulmonary disease (COPD)

      SARILUMAB*

      IL-6R Antibody
      Polymyalgia rheumatica, giant cell arteritis

      EVINACUMAB

      ANGPTL-3 Antibody
      Homozygous familial hypercholesterolemia (HoFH)

      REGN-EB3 (REGN3470-3471-3479)

      Ebola Virus Antibody
      Ebola virus infection

      FASINUMAB?

      NGF Antibody
      Chronic pain from osteoarthritis of the knee or hip

    Trials Footnotes

    * in collaboration with Sanofi

    ? in collaboration with Teva and Mitsubishi Tanabe

    This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.

    免费四虎库精品视倾